Clinical Trial: Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07703956) titled 'Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults' on July 06.

Brief Summary: This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed with DSM-5 schizophrenia who are in an acute exacerbation phase.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Schizophrenia

Intervention: DRUG: VV119 2mg

VV119 capsules 1 capsule (2mg/capsule) + VV119 capsules placebo 2 capsules + aripiprazole tablet placebo 2 tablets

DRUG: VV119 4mg

V...